|  |
| --- |
| **Table S4. Detailed characteristics of the patients analyzed by irGEP (*n* = 72)** |
| **Characteristic** | **No. of patients (%)a** |
| Median age (range), years | 67 (35–95) |
| Sex |  |
|  Male  |  43 (60) |
|  Female |  29 (40) |
| ECOG performance status |  |
|  0–1 |  42 (58) |
|  2 |  15 (21) |
|  3–4 |  8 (11) |
|  Unknown (not recorded) |  7 (10) |
| Smoking historyb |  |
|  Current or former |  43 (60) |
|  Never |  22 (31) |
|  Unknown (not recorded) |  7 (10) |
| Favorable subset |  15 (21) |
|  Neuroendocrine carcinoma (NEC) |  4 (6) |
|  Squamous carcinoma limited to cervical lymph nodes (HNC-like) |  7 (10) |
|  Adenocarcinoma restricted to axillary lymph nodes in females (BC-like) |  1 (1) |
|  Extragonadal germ cell tumor syndrome (GCT-like) |  1 (1) |
|  Peritoneal carcinomatosis in females (PPC-like) |  2 (3) |
|  Squamous carcinoma limited to inguinal lymph nodes (ACC-like)  |  0 (0) |
|  Single resectable metastatic carcinoma |  0 (0) |
| Unfavorable subset |  57 (79)**c** |
|  Multiple lymph nodes only metastasis |  19 (33) |
| Histology |  |
|  Squamous |  15 (21) |
|  Adeno |  32 (44) |
|  Undifferentiated |  18 (25) |
|  Other |  7 (10)d |
| Abbreviations: irGEP, immune-related gene expression profiling; ECOG, Eastern Cooperative Oncology Group. |
| aPercentages may not add up to 100 because of rounding. |
| bCurrent smokers were defined as individuals who had smoked ≥100 cigarettes including at least one within the year prior to diagnosis; former smokers as those who had smoked ≥100 cigarettes but had quit >1 year prior to diagnosis; and never-smokers as those who had smoked <100 cigarettes. |
| cA plausible primary site of origin was identified in one patient (primary differentiated thyroid carcinoma was identified after second-line chemotherapy in a patient with multiple bone metastases). |
| dAdenosquamous, *n* = 1; neuroendocrine carcinoma, *n* = 4; not otherwise specified, *n* = 2. |